Dermatomyositis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Dermatomyositis – Pipeline Review, H2 2017’, provides an overview of the Dermatomyositis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Dermatomyositis

The report reviews pipeline therapeutics for Dermatomyositis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Dermatomyositis therapeutics and enlists all their major and minor projects

The report assesses Dermatomyositis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Dermatomyositis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Dermatomyositis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dermatomyositis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bristol-Myers Squibb Co

Chugai Pharmaceutical Co Ltd

Eli Lilly and Co

Hope Pharmaceuticals Inc

Idera Pharmaceuticals Inc

KPI Therapeutics Inc

MedImmune LLC

Neovacs SA

Novartis AG

Octapharma AG

Pfizer Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Dermatomyositis - Overview 7

Dermatomyositis - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Products under Development by Companies 10

Dermatomyositis - Therapeutics Assessment 11

Assessment by Target 11

Assessment by Mechanism of Action 13

Assessment by Route of Administration 15

Assessment by Molecule Type 17

Dermatomyositis - Companies Involved in Therapeutics Development 19

Bristol-Myers Squibb Co 19

Chugai Pharmaceutical Co Ltd 19

Eli Lilly and Co 20

Hope Pharmaceuticals Inc 20

Idera Pharmaceuticals Inc 21

KPI Therapeutics Inc 21

MedImmune LLC 21

Neovacs SA 22

Novartis AG 22

Octapharma AG 23

Pfizer Inc 23

Dermatomyositis - Drug Profiles 25

abatacept - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

baricitinib - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

dalazatide - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

immune globulin (human) - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

IMO-8400 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

lenabasum - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

MEDI-7734 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

PF-06823859 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

siponimod - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

sodium thiosulfate - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

tocilizumab - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

tofacitinib citrate - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders - Drug Profile 105

Product Description 105

Mechanism Of Action 105

R&D Progress 105

Dermatomyositis - Dormant Projects 111

Dermatomyositis - Product Development Milestones 112

Featured News & Press Releases 112

Oct 31, 2017: Corbus Pharmaceuticals Announces New Patent Issuance Covering the Use of Anabasum for the Treatment of Inflammatory Diseases 112

Oct 19, 2017: Corbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis 112

Jul 19, 2017: Neovacs Announces FDA Acceptance of a New IND to Expand in U.S. IFN-alpha Kinoid Clinical Development Program in Dermatomyositis 114

May 17, 2017: FDA Grants Octapharma USA Orphan Drug Designation for Octagam 10% for the Treatment of Dermatomyositis 114

May 11, 2017: Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis 114

May 04, 2017: Neovacs to present clinical development update on IFNalpha Kinoid in dermatomyosis 115

Mar 09, 2017: Neovacs to present IFNalpha Kinoid technology and its clinical outlooks at upcoming Keystone Symposia Conference 116

Feb 09, 2017: Neovacs Issued New Broad Patent in China for IFNa Kinoid 116

Nov 29, 2016: Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis 116

Sep 28, 2016: Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation 117

Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis 118

Oct 13, 2015: Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum 119

Aug 06, 2015: Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015 119

Jul 13, 2015: Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab for the Treatment of Dermatomyositis 119

Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis 120

Appendix 122

Methodology 122

Coverage 122

Secondary Research 122

Primary Research 122

Expert Panel Validation 122

Contact Us 122

Disclaimer 123

List of Tables

List of Tables

Number of Products under Development for Dermatomyositis, H2 2017 8

Number of Products under Development by Companies, H2 2017 9

Products under Development by Companies, H2 2017 10

Number of Products by Stage and Target, H2 2017 12

Number of Products by Stage and Mechanism of Action, H2 2017 14

Number of Products by Stage and Route of Administration, H2 2017 16

Number of Products by Stage and Molecule Type, H2 2017 18

Dermatomyositis – Pipeline by Bristol-Myers Squibb Co, H2 2017 19

Dermatomyositis – Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017 20

Dermatomyositis – Pipeline by Eli Lilly and Co, H2 2017 20

Dermatomyositis – Pipeline by Hope Pharmaceuticals Inc, H2 2017 20

Dermatomyositis – Pipeline by Idera Pharmaceuticals Inc, H2 2017 21

Dermatomyositis – Pipeline by KPI Therapeutics Inc, H2 2017 21

Dermatomyositis – Pipeline by MedImmune LLC, H2 2017 22

Dermatomyositis – Pipeline by Neovacs SA, H2 2017 22

Dermatomyositis – Pipeline by Novartis AG, H2 2017 23

Dermatomyositis – Pipeline by Octapharma AG, H2 2017 23

Dermatomyositis – Pipeline by Pfizer Inc, H2 2017 24

Dermatomyositis – Dormant Projects, H2 2017 111

List of Figures

List of Figures

Number of Products under Development for Dermatomyositis, H2 2017 8

Number of Products under Development by Companies, H2 2017 9

Number of Products by Top 10 Targets, H2 2017 11

Number of Products by Stage and Top 10 Targets, H2 2017 11

Number of Products by Top 10 Mechanism of Actions, H2 2017 13

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 13

Number of Products by Routes of Administration, H2 2017 15

Number of Products by Stage and Routes of Administration, H2 2017 15

Number of Products by Molecule Types, H2 2017 17

Number of Products by Stage and Molecule Types, H2 2017 17

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports